AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18057338
Drug: Tesamorelin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesamorelin (2 mg daily subcutaneous injection for 26 weeks)
Trial: 1391977
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone treatment (Control)
Trial: 3999081
Drug: Diumide‐K Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diumide‐K Continus tablets
Trial: 3999081
Drug: Lasikal tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasikal tablets
Trial: 3999081
Drug: Lasix and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasix and Slow‐K tablets
Trial: 18309618
Drug: Airborne particle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Airborne particle abrasion with 50-microm Al2O3 + Silano-Pen + silane coupling agent (Bredent)
Trial: 18309618
Drug: Laboratory tribochemical
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laboratory tribochemical silica coating (110-microm Al2O3 + 110-microm SiOx) (Rocatec) + silane coupling agent (ESPE-Sil)
Trial: 18246859
Drug: Other antidepressant
RxNorm normalized name: Other antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antidepressant drugs
Trial: 12655908
Drug: Nonteratogenic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonteratogenic drugs
Trial: 10984014
Drug: Erdosteine syrup
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine syrup 3.5%
Trial: 10984014
Drug: Erdosteine sachets
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine sachets 225 mg
Trial: 10984014
Drug: Placebo (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for syrup 3.5%)
Trial: 10984014
Drug: Placebo (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for sachets 225 mg)
Trial: 20005744
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil (average effect site concentration 1.99 +/- 0.02 ng/mL) with epidural analgesia with 0.5% ropivacaine started at the beginning of anesthesia
Trial: 20005744
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil (average effect-site concentration 5.61 +/- 0.84 ng/mL) with epidural analgesia started and at the end of surgery
Trial: 16889593
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy of 10,000 lux/wide spectrum for 3 weeks
Trial: 1323624
Drug: Foscarnet maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet maintenance therapy
Trial: 1602361
Drug: No chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chronic antiviral therapy
Trial: 24577230
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) at three doses (200 mg, 400 mg, 800 mg/day) for 12 weeks
Trial: 20518807
Drug: Taranabant (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant (all doses)
Trial: 17952847
Drug: Common single-nucleotide
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common single-nucleotide polymorphisms (SNPs) in seven genes involved in HDL metabolism
Trial: 17952847
Drug: 660 polymorphisms
RxNorm normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 660 polymorphisms in eight genes not involved in HDL metabolism
Trial: 15817602
Drug: FEC followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FEC followed by high dose therapy (HDT) consisting of cyclophosphamide, thiotepa, and carboplatin with stem cell rescue
Trial: 15817602
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (5-fluorouracil, epirubicin, and cyclophosphamide - FEC for six cycles)
Trial: 12219032
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous insulin at a rate of at least 1.5 microU/kg/min to maintain serum glucose levels between 100 to 140 mg/dL
Trial: 10367025
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate at 300 mg load
Trial: 10367025
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate at 300 mg load
Trial: 10367025
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate at 1000 mg load
Trial: 10367025
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate at 1000 mg load
Trial: 10367025
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate vs. calcium citrate at 1000 mg load (urinary increment method)
Trial: 924791
Drug: Danitracene 1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danitracene 1-3 x 0.5 mg/day for 1-3-6 months
Trial: 924791
Drug: Danitracene 1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danitracene 1-3 x 0.5 mg/day
Trial: 29088439
Drug: Manual CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual CC
Trial: 25743937
Drug: Lenalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (25 mg) with docetaxel (75 mg/m²) and prednisone (5 mg twice daily)
Trial: 25743937
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with docetaxel (75 mg/m²) and prednisone (5 mg twice daily)
Trial: 25743937
Drug: Lenalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (25 mg)
Trial: 23902779
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid and vitamin B-12 combination
Trial: 19371315
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg b.i.d. for 7 days
Trial: 19371315
Drug: Carbamazepine titrated
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine titrated up to 200 mg b.i.d. over 20 days
Trial: 11093555
Drug: Screening plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening plus treatment for those with previous ulcers
Trial: 9181277
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (2 micrograms/kg/min for two hours)
Trial: 1327049
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (400 micrograms twice daily for 5 days)
Trial: 1327049
Drug: Inhaled PAF
RxNorm normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled PAF (total cumulative dose of 500 micrograms)
Trial: 3908329
Drug: Disopyramide (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide (7 mg/kg per day)
Trial: 3908329
Drug: Amiodarone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (200 mg)
Trial: 27161860
Drug: Buprenorphine-naloxone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone therapy for 12 weeks
Trial: 22432104
Drug: Lixisenatide 2-step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 2-step (10 μg for 1 week, 15 μg for 1 week, then 20 μg)
Trial: 22432104
Drug: Lixisenatide 1-step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 1-step (10 μg for 2 weeks, then 20 μg)
Trial: 20562069
Drug: Elixir DESyne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elixir DESyne Novolimus Eluting Coronary Stent System (NES)
Trial: 2109927
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) infusion (5 ng/kg/min for 72 hours)
Trial: 7010886
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg x 3) added if IOP uncontrolled
Trial: 7010886
Drug: Timolol once
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol once a day administration
Trial: 31734151
Drug: Foot massage
RxNorm normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot massage therapy (10-minute sessions, twice during one day, within 30 minutes after opioid pain medication)
Trial: 30680852
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of varenicline (extended treatment)
Trial: 30680852
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of varenicline plus 12 weeks of placebo (standard treatment)
Trial: 26360979
Drug: Verapamil-nitroglycerin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil-nitroglycerin (30 μmol/L each)
Trial: 8557121
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a)
Trial: 19688314
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs (ATH group)
Trial: 11904526
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clopidogrel and ASA
Trial: 10559611
Drug: Oral bropirimine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bropirimine (3 g/day for 3 consecutive days with a 4-day drug-free interval for up to 1 year)
Trial: 10559611
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG (weekly for 2 x 6 weeks)
Trial: 10559611
Drug: Oral bropirimine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bropirimine
Trial: 2350615
Drug: Pamidronate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (1 mg/kg body wt.) by infusion over 4 h
Trial: 2350615
Drug: Pamidronate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (1 mg/kg body wt.) by infusion over 24 h
Trial: 7011531
Drug: PIP (6-mercaptopurine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIP (6-mercaptopurine daily and a prednisone pulse every three months)
Trial: 29914146
Drug: Quinoa-enriched bread
RxNorm normalized name: quinoa oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinoa-enriched bread (providing 20 g quinoa flour)
Trial: 27893654
Drug: Vaccine A
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine A
Trial: 27893654
Drug: Vaccine B
RxNorm normalized name: meningococcal vaccine B and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine B
Trial: 27893654
Drug: Vaccine C
RxNorm normalized name: Hepatitis vaccine combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine C
Trial: 27893654
Drug: Vaccine D
RxNorm normalized name: hepatitis B adult vaccine dialysis 40 mcg/mL intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine D
Trial: 20613470
Drug: Remifentanil (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0, 2, and 4 ng/ml)
Trial: 14508155
Drug: Antibiotic use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic use and infection control practices
Trial: 7793587
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) - parenteral cefotaxime, oral and enteral polymyxin E, tobramycin, and amphotericin B
Trial: 28928556
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol (Group II)
Trial: 23764350
Drug: siponimod 0.25
RxNorm normalized name: siponimod 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod 0.25 mg
Trial: 23764350
Drug: siponimod 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod 0.5 mg
Trial: 23764350
Drug: siponimod 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod 1.25 mg
Trial: 23764350
Drug: siponimod 2
RxNorm normalized name: siponimod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod 2 mg
Trial: 23764350
Drug: siponimod 10
RxNorm normalized name: SIPONIMOD
DrugBank: Siponimod (DB12371)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: siponimod 10 mg
Trial: 15581196
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone (1 mg/daily)
Trial: 11722323
Drug: Carbamazepine treatment
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine treatment (stable dose)
Trial: 7651920
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with antiviral drugs
Trial: 28301614
Drug: HP/TAZ lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP/TAZ lotion (halobetasol propionate 0.01% and tazarotene 0.045%)
Trial: 24169346
Drug: Tivantinib 360
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib 360 mg BID with erlotinib for extensive metabolisers (EMs)
Trial: 24169346
Drug: Tivantinib 240
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib 240 mg BID with erlotinib for poor metabolisers (PMs)
Trial: 24169346
Drug: Pharmacokinetics profile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics profile of tivantinib
Trial: 22087066
Drug: Calligraphy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calligraphy therapy (intensive calligraphy training for eight weeks)
Trial: 22087066
Drug: No calligraphy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No calligraphy treatment (control group)
Trial: 18724864
Drug: Non-surgical mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical mechanical periodontal treatment in the second trimester of pregnancy
Trial: 16413592
Drug: Trivalent live‐attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent live‐attenuated influenza virus vaccine (LAIV, FluMist)
Trial: 15477795
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs with renoprotective properties; specific types include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium antagonists, beta-blockers, and diuretics; dosage and duration not specified.
Trial: 11229849
Drug: Candidate vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate vaccines (low, medium, high doses)
Trial: 11229849
Drug: Candidate vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate vaccines
Trial: 3324618
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/48 hours) + dipyridamole (300 mg/day)
Trial: 3324618
Drug: Dipyridamole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (400 mg/day)
Trial: 24001364
Drug: Guided Internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-delivered cognitive behavioural therapy (CBT) for insomnia over 6 weeks
Trial: 16152839
Drug: Rhubarb and
RxNorm normalized name: Rhubarb and salicylic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb and Sanchi Powder (RSP) - 3g of rhubarb and 2g of Sanchi Powder orally, 3-4 times daily
Trial: 11682582
Drug: 0.50 g
RxNorm normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 g of protein x kg(‐1) x day(‐1)
Trial: 11682582
Drug: 0.75 g
RxNorm normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 g of protein x kg(‐1) x day(‐1)
Trial: 11682582
Drug: 1.00 g
RxNorm normalized name: Niacinamide 1.00 g in 50 mL TOPICAL LIQUID [by selected hyaluron day serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.00 g of protein x kg(‐1) x day(‐1)
Trial: 2975291
Drug: Isradipine 10
RxNorm normalized name: isradipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 10 mg
Trial: 2975291
Drug: Isradipine 20
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine 20 mg
Trial: 31342057
Drug: Outpatient parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient parenteral antimicrobial therapy plus buprenorphine treatment
Trial: 31342057
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (inpatient intravenous antibiotic completion)
Trial: 27477896
Drug: Placebo (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (24 mL saline solution)
Trial: 23713304
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection at trigger points
Trial: 18814407
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Simvastatin (universal use)
Trial: 18814407
Drug: 0.5 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mmol/L reduction in total cholesterol
Trial: 18814407
Drug: 1.0 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mmol/L reduction in total cholesterol
Trial: 18814407
Drug: 1.5 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mmol/L reduction in total cholesterol
Trial: 18814407
Drug: 2.0 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mmol/L reduction in total cholesterol
Trial: 11147929
Drug: G(‐463)A polymorphism
RxNorm normalized name: Angelica polymorpha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G(‐463)A polymorphism of myeloperoxidase (MPO) gene
Trial: 1464895
Drug: Trandolapril 8
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril 8 mg
Trial: 1464895
Drug: Trandolapril (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (2, 4, 8 mg)
Trial: 28668774
Drug: Repeat lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat lactate ≥ 5 mmol/L
Trial: 26891150
Drug: 20% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% human albumin (100, 200, or 300 ml based on preoperative serum albumin level)
Trial: 2077596
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of saline at 37 degrees C
Trial: 231324
Drug: Phanurane (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phanurane (2 gelules daily, 2 X 50 mg of canrenone)
Trial: 28192854
Drug: TRP agonist
RxNorm normalized name: Trp
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TRP agonist
Trial: 23621350
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg rBet v 1‐FV
Trial: 23621350
Drug: 80 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 μg rBet v 1‐FV
Trial: 23621350
Drug: 160 μg
RxNorm normalized name: immunoglobulin G, human 160 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 μg rBet v 1‐FV
Trial: 23621350
Drug: 320 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 μg rBet v 1‐FV
Trial: 22185606
Drug: Educational supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational supportive therapy in a group (placebo, 6 sessions)
Trial: 22185606
Drug: Educational supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational supportive therapy in a group (placebo)
Trial: 19422286
Drug: BEMER magnetic
RxNorm normalized name: Beser
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BEMER magnetic field treatment for 8 minutes twice daily for 12 weeks
Trial: 15019375
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% and timolol 0.5% once daily
Trial: 15019375
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% and timolol 0.5% twice daily
Trial: 3493333
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (blind, placebo-controlled protocol)
Trial: 3493333
Drug: Intravenous naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous naloxone (double-blind, placebo-controlled protocol)